Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Stryker Corp (NYSE: SYK) reported second-quarter results that topped the consensus forecast. It posted an adjusted EPS of $2.25, a stupendous increase from $0.64 a year ago, better than the Wall Street estimate of $2.12.

Stryker Boosts Q2 Earnings, Margins After Clocking 55% Jump In Sales As Pandemic Moderates

Stryker Corporation's (SYK) CEO Kevin Lobo on Q2 2021 Results - Earnings Call Transcript

Kalamazoo, Michigan, July 27, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2021:

Stryker reports second quarter 2021 operating results

Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stryker (SYK) Earnings Expected to Grow: Should You Buy?

Stryker (SYK) introduces new Tornier shoulder arthroplasty portfolio enabling the company to strengthen its position in the shoulder market.

Stryker (SYK) Unveils Tornier Shoulder Arthroplasty Portfolio

More than a decade after receiving European CE mark approval, an implantable balloon spacer, InSpace, recently acquired by Stryker Corp (NYSE:SYK), will make its U.S. debut after FDA approval. The InSpace device is placed in the subacromial space of the shoulder to help heal a torn rotator cuff.

FDA OK's Stryker's Implantable, Biodegradable Balloon Spacer For Shoulder Injury

Royal Philips

PHG vs. SYK: Which Stock Is the Better Value Option?

PHG or SYK: Which Is the Better Value Stock Right Now?

Air Products and Chemicals

Bristol-Myers

Comcast

Cisco Systems

General Dynamics

Illinois Tool Works

Mastercard

This article series presents upcoming ex-dividend dates. We provide a summary table with relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: June 29-July 12, 2021

Kalamazoo, Michigan, June 24, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host a conference call on Tuesday, July 27, 2021 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended June 30, 2021 and provide an operational update. Final operating results for the quarter ended June 30, 2021 will be released at 4:05 p.m. that day.

Stryker to host conference call on July 27, 2021

JPMorgan Chase & Co

Medtronic

T. Rowe Price Group

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: June 22-July 5, 2021

FUJIFILM Holdings Corp

Olympus is a leading medtech company that offers predictable earnings growth, an optimized portfolio and engages with activist investors to deliver better shareholder returns.

Olympus: Medtech With Optimized Portfolio And Predictable Earnings Growth

Roblox

The broad markets tipped lower at the close on Wednesday. The one sector that had a solid move was health care, with an emphasis on drug manufacturers.

What Jim Cramer Likes About Roblox, Stryker and More

Phibro Animal Health

PAHC vs. SYK: Which Stock Is the Better Value Option?

Johnson & Johnson

Zimmer Biomet Hlds

As hospitals address the major backlog of pandemic-postponed elective surgeries, medical device makers -- and their stock prices -- could benefit.

This Part of the Reopening Trade Is Just Getting Started

Stryker Corp.'s ( SYK , Financial) business was severely impacted by Covid-19 in 2020 as elective surgical procedures were postponed or canceled as the health care industry dealt with the pandemic. Organic growth rates for the company, which have been historically above that of peers, were down last year.

Why Stryker Is an Excellent Dividend Growth Stock

Stryker (SYK) reported earnings 30 days ago. What's next for the stock?

Why Is Stryker (SYK) Down 2.8% Since Last Earnings Report?

Stryker Corp. is a major leader in many of the categories it plays in. The company has done well to capitalize on a growing market and it has created value for itself as a result.

Stryker Corp.: A Market Leader Demands A Premium

Boston Scientific

Molson Coors Brewing

Autodesk

Allied Esports Entertainment Inc

Exact Sciences

Gap Inc

Constellation Brands

With the trading day more than halfway over, the markets had dipped after a relatively strong start to the day.

Boston Scientific, Gap, Molson Coors and More Tuesday Afternoon Analyst Calls

Stryker is a market-leading medical technology company for orthopedics, surgical implants, and operating room equipment. It should benefit from the growing wave of healthcare spend, and continues to expand its moat through strategic M&A.

If You Want A Fast-Growing SWAN, Then Consider Stryker Corp.

PAHC vs. SYK: Which Stock Should Value Investors Buy Now?

MAHWAH, N.J.--(BUSINESS WIRE)--Stryker will showcase its new, combined foot and ankle portfolio at 2021 American College of Foot and Ankle Surgeons Vegas Conference from May 18-21.

Stryker to Showcase New, Combined Foot and Ankle Portfolio at 2021 ACFAS Vegas Scientific Conference

Northrop Grumman

YUM! Brands

You may think dividend investing is all about that yield, but you shouldn't turn a blind eye to growth as well. The post 3 Dividend Stocks for Growth and Total Returns appeared first on InvestorPlace.

3 Dividend Stocks for Growth and Total Returns

Align Technology

Ford Motor Company

Freeport-McMoRan

Hilton Worldwide Holdings

Take-Two Interactive Software

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

We discuss seven hot stocks to buy that could gain traction in the rest of the year The post 7 Hot Stocks To Buy Now For A Summer Of Reopenings appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn't matter if you have $500 in savings or $5 million.

7 Hot Stocks To Buy Now For A Summer Of Reopenings

Asensus Surgical

Intuitive Surgical

Rapid innovation is boosting the robotic surgery space, putting the spotlight on Johnson & Johnson (JNJ), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG) and Asensus Surgical (ASXC).

News for Stryker Stock (SYK)